This post hoc analysis of the ISAR-REACT 5 trial included 1565 patients with ACS presenting off-hours and 2453 patients presenting on-hours, randomized to ticagrelor or prasugrel. The primary endpoint was a composite of deat...
Are All Class I Antiplatelets and Composite Outcomes Created Equal? An Analysis of the ISAR-REACT 5 TrialKatrina D'Amore DO, MPH Guest Contributor aAnand Swaminathan MD, MPH Guest Contributor bAnnals of Emergency Medicine
\{BIVALIRUDIN\} \{VERSUS\} \{ABCIXIMAB\} \{AND\} \{HEPARIN\} \{IN\} NSTEMI: \{LESSONS\} \{FROM\} \{THE\} \{INTRACORONARY\} \{STENTING\} \{AND\} \{ANTITHROMBOTIC\} REGIME: \{RAPID\} \{EARLY\} \{ACTION\} \{FOR\} \{CORONARY\} \{TREATMENT\} (ISAR-REACT-4) \{TRIAL\}...
Abciximab/heparin vs bivalirudin for NSTEMI: ISAR-REACT 4 trial – 1 yearAbciximab/heparin vs bivalirudin for NSTEMI ISARREACT trialEurointervention
法国,巴黎-2019年9月1日:普拉格雷在减少急性冠脉综合征患者介入治疗后的缺血性事件方面优于替格瑞洛,且普拉格雷治疗不增加出血风险。ISAR-REACT 5试验的最新结果今天在2019年ESC大会和世界心脏病大会(World Congress of Cardiology)上公布,并发表在《新英格兰医学杂志》(New England Journal of Medicine)上。
1001-8 Long-term results of ISAR-REACT: A randomized trial evaluating Abciximab in patients with elective percutaneous coronary intervention after pretreatment with a high loading dose of clopidogrel1001-8 long-term results of isar-react: a randomized trial evaluating abciximab in patients with elec...